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Abstract 
Background: To alleviate the interpretation of the core Alzheimer's disease (AD) 
cerebrospinal fluid (CSF) biomarkers amyloid β1-42 (Aβ42), total tau (T-tau) and 
phosphorylated tau (P-tau), the Erlangen Score (ES) interpretation algorithm has been 
proposed. 
 
Objective: In this study, we aim to assess the predictive properties of the ES algorithm on 
cognitive and neuroimaging outcomes in mild cognitive impairment (MCI).  
 
Methods: All MCI subjects with an available baseline CSF sample from ADNI-1 were included 
(n=193), and assigned an ES between 0 and 4 based on their baseline CSF biomarker profile. 
Structural magnetic resonance imaging brain scans and MMSE and ADAS-Cog scores were 
collected at up to 7 times in follow-up examinations. 
 
Results: We observed strong and significant correlations between the ES at baseline and 
neuroimaging and cognitive results with patients with neurochemically probable AD (ES = 4) 
progressing significantly (p ≤ 0.01) faster than those with a neurochemically improbable AD 
(ES = 0 or 1), and the subjects with neurochemically possible AD (ES = 2 or 3) in-between 
these two groups. 
 
Conclusion: This study further demonstrates the utility of the ES algorithm as a as a tool in 
predicting cognitive and imaging progression in MCI patients. 
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Introduction 
The importance of cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) as an aid 
for diagnostic decisions and a measure of disease progression is growing, both in research and in 
the clinical setting [1-3]. Reaching early and dependable diagnosis and prognosis for patients 
with memory complaints and other cognitive symptoms is likely key to be able to in time 
administer future treatments minimizing irreparable damage to the central nervous system [4]. A 
well-established panel of CSF biomarkers might be able to provide needed support in this task. 
The four most prominent and widely used biomarkers to date reflect different aspects of AD 
pathology: deposition of amyloid plaques leading to decreased concentrations of CSF amyloid 
β1-42 (Aβ42) and decreased Aβ42/40 ratio; neuronal degeneration as reflected by total tau (T-tau); 
and neurofibrillary tangle formation correlated to phosphorylated tau (P-tau) [5, 6]. However, 
inter-laboratory differences in biomarkers assays, analytical procedures and pre-analytical 
sample collection protocols have made it hard to establish laboratory-independent cutoff values 
[7]. This leads to difficulties in comparing CSF results between centers, and even within a given 
center if a measurement method and/or preanalytical handling protocol are changed. To alleviate 
the interpretation of laboratory analysis results in AD, the Erlangen Score (ES) interpretation 
algorithm (ES) has previously been proposed [8]. The ES categorizes subjects into five ordinal 
categories with scores from 0 to 4 based on their CSF biomarker profile in relation to cutoff 
values that are given laboratory-specific. This approach reflects reality closer than the 
dichotomization into normal or pathologic biomarker status used in other studies [9, 10]. The ES 
algorithm has previously been validated in pre-dementia subjects in two multicenter studies, and 
its utility was supported by strong associations to the development of AD dementia (ADD) [11-
13]. However, the relation of the ES to cognitive and neuroradiological measures of the disease 
progression in mild cognitive impairment (MCI) stage of AD has never been investigated. 
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Therefore, in this study we aimed to assess the validity of the ES algorithm as a tool for 
predicting cognitive and imaging progression in MCI. We hypothesized that a higher score 
would be associated with faster disease progression. 
 
 
Methods 
Data used in the preparation of this article were obtained from the Alzheimer’s disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). ADNI was launched in 2003 by 
the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and 
Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical 
companies and non-profit organizations as a $60 million, 5-year public-private partnership. 
The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), 
positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of MCI and early 
AD. The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical 
Center and University of California – San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and private corporations, and 
subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of 
ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. 
To date these three protocols have recruited over 1500 adults, ages 55 to 90, to participate in 
the research, consisting of cognitively normal older individuals, people with early or late 
MCI, and people with early AD. The follow up duration of each group is specified in the 
protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and 
ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see 
www.adni-info.org, where inclusion/exclusion criteria are also described in detail. 
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Subjects 
Our study population consisted of all MCI subjects with available baseline CSF samples from 
ADNI-1 (n=193). Briefly, all subjects included in ADNI-1 were between the ages of 55 and 
90 years, had completed at least 6 years of education, were fluent in Spanish or English, and 
were free of any significant neurologic disease other than AD. The MCI group had Mini 
Mental State Examination (MMSE) score ≥24, objective memory loss as shown on scores on 
delayed recall of the Wechsler Memory Scale Logical Memory II (>1 standard deviations 
below the normal mean), Clinical Dementia Rating scale 0.5, preserved activities of daily 
living, and absence of dementia.  
 
Erlangen Score 
All study subjects were assigned an ES between 0 and 4 based on their CSF biomarker profile 
with a macro written in Microsoft Excel. The detailed protocol for the ES can be found 
elsewhere [8]. Briefly, a CSF profile with all biomarkers normal is scored 0 points; a pattern 
with only slight alterations in one biomarker group (either Aβ or Tau, but not both) results in 
the score of 1; alterations in amyloid β pathology (in this particular study, decreased Aβ1-42 
concentrations) or tau metabolism (increased concentrations of T-tau and/or P-tau) but not in 
both pathologies is scored 2 points; a result with clear alterations in one biomarkers’ group 
(either Aβ or Tau) accompanied by marginal alterations in the other group is scored 3 points; 
clear alterations in both Aβ and T-tau/P-tau result in 4 points. A simplified rendition of the 
interpretation algorithm used to translate the biomarker profiles of each subject is described 
elsewhere. Eventually, the subjects with the score of 0-1 are defined as "neurochemically 
improbable AD", the subjects with the score of 2-3 are defined as "neurochemically possible 
AD", and the subjects with the score of 4 are defined as "neurochemically probable AD". 
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CSF measurements 
CSF collection, processing and storage procedures have been described previously [14]. CSF 
Aβ42, T-tau and P-tau were measured using the multiplex xMAP Luminex platform 
(Luminex Corp, Austin, TX, USA) with the INNOBIA AlzBio3 kit (Fujirebio, Ghent, 
Belgium). The reference ranges used for the calculations of the scores were taken directly 
from the previous study [14], and applied for this study without further modifications: 192 
pg/mL for Aβ1-42, 93 pg/mL for T-tau, and 23 pg/mL for P-tau. The border zones, defining 
"slight alterations", were set as the concentrations within the range of 173 - 192 pg/mL for 
Aβ1-42, within 93-102 pg/mL for T-tau, and within 23-25 pg/mL for P-tau. 
 
Magnetic resonance imaging 
Structural magnetic resonance imaging brain scans were acquired using 1.5 Tesla MRI 
scanners (up to 7 time points: screening, and 6, 12, 18, 24, 36 and 48 months) with a 
standardized protocol including T1-weighted MRI scans using a sagittal volumetric 
magnetization prepared rapid gradient echo (MP-RAGE) sequence [15]. In brief, automated 
volume measures were performed with FreeSurfer software package 
(http://surfer.nmr.mgh.harvard.edu/fswiki) [16, 17]. We used averaged volume measurements 
for the right and left hippocampi for this study. 
 
Cognitive assessments 
Overall cognition was assessed by the Mini Mental State Examination (MMSE) and the 
Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) tests at up to 7 time 
points (screening, and at 6, 12, 18, 24, 36 and 48 months after the baseline assessment). 
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Statistical analysis 
If not stated otherwise, the results of continuous variables are presented as means and 
standard deviations (std. dev.) or as medians and inter-quartile ranges (IQR). ANOVA and χ2 
statistics were used to test differences in age and sex distribution, baseline measurements of 
hippocampal and whole brain volumes, and baseline MMSE and ADAS-Cog scores between 
the study groups. Generalized Estimating Equation (GEE) was used to discern statistical 
differences between ES groups in the development of MMSE scores, ADAS-Cog scores, 
hippocampal volumes and whole brain volumes over time. The interaction term of ES*month 
from baseline was used to test modifying effects of the ES on the effect of the observation 
time. All longitudinal changes in MMSE, ADAS-Cog scores, whole brain volumes, and 
hippocampal volumes were normalized to a percentage change in relation to their baseline 
values. Statistical signiﬁcance was determined at the p < 0.05 level. All statistics, charts, and 
tables were generated with SPSS version 22 (IBM, New York, USA).  
Ethics 
All CSF samples analyzed in this study were collected in accordance with regional ethical 
guidelines as well as the ethical standards of the Helsinki Declaration of 1975. 
 
Results 
Demographics of the study cohort 
Demographics and the baseline measures of the metrics analyzed in this study are presented in 
table 1. There were no significant differences in age between the groups. There were 
significant differences in the sex distribution between the groups (p = 0.02). The group with 
neurochemically improbable AD (ES = 0 or 1) had 26% female subjects, the group with 
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neurochemically possible AD (ES = 2 or 3) had 18% female subjects, and the group with 
neurochemically probable AD (ES = 4) had 40% female subjects.  
Subjects in the neurochemically improbable AD group had significantly larger hippocampal 
volumes at baseline compared to the neurochemically possible (mean diff = 718 mm3, p = 
0.03) and the neurochemically probable (mean diff = 777 mm3, p = < 0.01) AD groups. There 
were no significant difference in hippocampal volumes between the neurochemically possible 
and probable groups (p = 1.0). 
The neurochemically improbable AD subjects also had significantly larger whole brain 
volumes at baseline compared to those with neurochemically probable AD (mean diff = 6.9E5 
mm3, p < 0.01) but not compared to the subjects with neurochemically possible AD  (p = 1.0). 
The neurochemically possible group and the neurochemically probable group did not 
significantly differen in baseline whole brain volumes (p = 0.11).  
The neurochemically improbable AD group registered lower ADAS-Cog scores at baseline 
compared to the neurochemically possible AD (mean diff = 5.5, p < 0.01) and the 
neurochemically probable AD (mean diff = 5.5, p < 0.01) groups. No significant differences 
in ADAS-Cog scores between the neurochemically possible and probable AD groups could be 
found (p = 1.0). 
The neurochemically improbable AD group presented higher MMSE scores than the 
neurochemically possible AD (mean diff = 1.0, p = 0.04) but not the neurochemically 
probable group (p = 0.20). There were, again, no significant differences between the 
neurochemically possible and probable AD groups (p = 0.64). 
 
Longitudinal changes in cognitive measures in the MCI group 
Follow-times and and number of participants at each point of follow-up is presented in table 
2. MMSE scores declined significantly faster in the subjects with neurochemically possible 
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AD (B = -0.20, p = 0.03) and with neurochemically probable AD (B = - 0.36, p < 0.01) 
compared to the subjects with neurochemically improbable AD (fig. 1a).  There was a 
nonsignificant tendency towards faster decline in the MMSE score in neurochemically 
probable subjects compared to neurochemically possible subjects (B = - 0.16, p = .10). 
 
Subjects with neurochemically probable AD also increased faster in ADAS-Cog scores as 
compared to the subjects with improbable AD (B = 0.71, p = 0.01, fig. 1b). We did not 
observe differences in ADAS-Cog scores increase between the neurochemically possible AD 
subjects compared to the neurochemically improbable AD subjects (B = 0.10, p = 0.76). 
There were however a significant difference in decline between the neurochemically probably 
and neurochemically possible AD subjects (B = 0.60, p = 0.02). 
 
Longitudinal changes in brain structure in MCI 
Whole brain volumes decreased faster in subjects with neurochemically possible AD (B = -
0.032, p = 0.03) and neurochemically probable AD (B = -0.066, p < 0.01) as compared to 
subjects with neurochemically improbable AD (fig. 1c). Whole brain volumes also decreased 
faster in subjects with neurochemically probable AD (B = -0.034, p = 0.01) as compared to 
subjects with neurochemically possible AD. 
 
Hippocampal volumes of patients with neurochemically possible AD (B = -0.084, p < 0.01), 
and neurochemically probable AD (B = -0.20, p < 0.01) decreased at a faster pace compared 
to the subjects with neurochemically improbable AD (fig. 1d). This was also true for subjects 
with neurochemically probable AD (B = -0.117, p < 0.01) as compared to subjects with 
neurochemically possible AD. 
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Discussion 
In this study, we examined the utility of the Erlangen Score as a globally implementable 
composite AD biomarker evaluation algorithm to predict cognitive and brain imaging decline 
in MCI stage of AD. We found that a higher ES predicted a faster disease progression in MCI 
patients; the subjects with higher ES showed a faster reduction of the whole brain and the 
hippocampal volumes, as well as faster decrease in MMSE, and a faster increase in ADAS-
Cog scores. 
 
In all disease progress measures selected for this study there were clear and statistically 
significant distinctions between patients with neurochemically improbable AD (ES of 0-1) 
and those with neurochemically probable AD (ES of 4), and for most measures also between 
the subjects with neurochemically improbable AD and those with neurochemically possible 
AD (ES = 2 or 3). Expectedly, subjects with ES 2-3 exhibited disease developing patterns in 
between those with the scores score 0-1 and 4. Here, the differences between the groups were 
statistically weaker, probably at least partly due to the low number of subjects with ES 2 and 
3 (n = 27 and n = 7, respectively). However, their statistical parameters in the GEE models as 
well as visual indications in the Loess regressions in figure 1 corroborate them being part of a 
continuum between the higher subject count groups of neurochemically improbable AD and 
neurochemically probable (ES = 4) AD. An interesting feature of the differences in the 
correlations of the cognitive and the structural measures and ES, is that the neurochemically 
improbable AD and the neurochemically possible AD divert from each other in structural but 
not in cognitive measures. One explanation for this might be that, in AD, structural decay can 
be radiologically visualized before cognitive decline can be detected by MMSE or ADAS-
Cog [18]. This means, that the subjects with no or only moderate CSF alterations (i.e. those 
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with ES = 0-3) are most probably at a stage of the disease when the structural changes can 
already be seen, but the cognitive decline has not yet reached pathological levels. To our best 
knowledge, ES is the first modality/biomarker reported so far capable to predict as small as 
10% drop in the MMSE score in a timespan of less than 24 months (see fig. 1a). 
 
It should be noted that figure 1 is intended as an illustration, while the GEE model provide 
statistical proof of differences. Some seeming anomalies between the GEE results and the 
graphical representations of data in the local regression illustrations occur. For instance the 
local regression lines representing the MMSE progression of the improbable and the possible 
AD groups cross paths, but still differ significantly in the GEE model. This likely stem from 
the linear nature of the GEE model contrasting with the adaptive nature of the local 
regression, and also the low number of participants, particularly at follow up, in the 
neurochemically probable AD group.  
 
Interestingly, in our recent study we found that MCI patients with neurochemically possible 
AD had, compared to the patients with neurochemically improbable AD, 6 - 8 times higher 
hazards to progress to the dementia stage of AD in the first three follow up years, and then 
their hazards decreased and became comparable to those with improbable AD; on the other 
hand, MCI patients with neurochemically probable AD had hazards to develop AD dementia 
8 - 12 times higher compared to the patients with neurochemically improbable AD [13]. 
 
The most serious limitation of this study is the unavailability of results of CSF Aβ1-40 in this 
cohort, which precluded integration of the Aβ42/40, a biomarker known to better reflect the 
amyloid β pathology than Aβ1-42 concentration [19, 20], into the calculation of the ES. This 
can perhaps explain, why some subjects categorized as neurochemically improbable AD 
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based on the three available CSF biomarkers (ES = 0 or 1), show progression in neuroimaging 
modalities (see fig. 1c and d). Certainly, some of these subjects would move to the 
neurochemically possible AD category (ES = 2 or 3), if their Aβ42/40 ratio had been available 
and turned out pathologic. Nevertheless it must be stressed that even in the absence of 
Aβ42/40 ratio, the interpretation based on the ES performed very well in this validation study.  
 
The findings of this study outline a new property of the ES that has not been demonstrated 
before, namely its predictive features of disease progression rates in MCI. This adds to the 
value of the algorithm that has previously been shown, including: (a) precise estimation of 
risk to develop dementia in pre-dementia AD. (b) Allowing inter-laboratory comparisons of 
lab test results, despite use of different assays and biomarker cut-offs between centers. (c) 
Interpretation and presentation of all possible biomarker patterns, including those that are 
inconsistent with hallmark AD-like biomarker patterns. 
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Table 1 Demographics and the cognitive and neuroimaging results. M/F, number of the male/female subjects; Mdn., median; IQR, inter-quartile 
range; Std. dev., standard deviation; MMSE, mini-mental state examination; ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive 
subscale; E3, *103; E6, *106. All measures were collected at the baseline. 
 
Erlangen score  Sex Age (years)  MMSE (points) ADAS-Cog (points) Whole brain volume (mm3) Hippocampal volumes (mm3) 
 M/F Mean (Std.dev.) Mdn (IQR) Mean (Std.dev.) 
Mdn 
(IQR) 
Mean (Std.dev.) Mdn (IQR) Mean (Std.dev.) Mdn (IQR) Mean (Std.dev.) Mdn (IQR) 
0-1 12/35 73.8 (7.9) 74 (67.5-80.4) 27.4 (1.7) 28 (26-29) 14.8 (5.4) 15.8 (11.3-17.3) 1.05E6 (.12E6) 1.05E6 (0.98E6-1.08E6) 6.98E3 (1.28E3) 7.20E3 (6.05E3-7.68E3) 
2-3 6/28 76.8 (7.5) 77.2 (73.9-80.9) 26.4 (1.9) 26 (25-28) 20.3 (6.2) 19.9 (15.7-24.7) 1.04E6 (0.12E6) 1.07E6 (0.96E6-1.13E6) 6.26E3 (1.28E3) 6.50E3 (5.34E3-7.11E3) 
4 45/67 78.1 (7.1) 79.1 (70.3-85.9) 26.9 (1.8) 27 (25-28) 20.3 (6.0) 21 (16.3-24.3) 0.99E6 (0.10E6) 0.98E6 (0.92E6-1.05E6) 6.20E3 (0.87E3) 6.11E3 (5.57E3-6.75E3) 
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Table 2 Participants at follow-up times 
 
Follow-up 
 Baseline 
6 
months 
12 
months 
18 
months 
24 
months 
30 
months 
36 
months 
42 
months 
48 
months 
54 
months 
Erlangen 
score 
0 or 1 47 45 43 40 36 33 30 21 6 3 
 
2 or 3 34 33 31 29 27 27 22 10 5 3 
  4 112 108 106 98 91 81 75 36 16 10 
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Figure legends 
Fig. 1. Correlations between follow up time and the neuropsychologic and neuroimaging 
population-averaged (marginal) metrics in the three ES categories: 
1a. MMSE score change from the baseline; 
1b. ADAS-Cog score change from the baseline; 
1c. whole brain volume change from the baseline; 
1d. hippocampal volume change from the baseline. 
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